Dong Sung Bio Pharm.Co.,Ltd. (002210.KS) Stock

002210.KS logo

Dong Sung Bio Pharm.Co.,Ltd.

002210.KSSouth Korea
Healthcare

Company profile

Dong Sung Bio Pharm.Co.,Ltd. reported revenue of 87.17 billion KRW for fiscal year 2025, down 1.4% from fiscal year 2024. Our analysis of its filings shows revenue shrinking from 88.59 billion KRW in fiscal year 2023 to 87.17 billion KRW in fiscal year 2025, 0.8% a year on average. Dong Sung Bio Pharm.Co.,Ltd. reports about 298 full-time employees.

What stands out

  • It reported a net loss in each of its last 5 fiscal years; the loss widened from 7.25 billion KRW in fiscal year 2024 to 25.74 billion KRW in fiscal year 2025.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Dong Sung Bio Pharm.Co.,Ltd.

Dong Sung Bio Pharm.Co.,Ltd. manufactures and sells pharmaceuticals and cosmetics in South Korea. The company offers over the counter drugs, such as emollient, vitamin supplement, alopecia treatment, antihistamines, liver disease treatment, fire extinguisher solvent, antiviral, eye drops, menopause treatment, sleep inducer, antipyretic, analgesic, anti-inflammatory, vascular reinforcement, broad-spectrum skin disease treatment, gum disease treatment, blood circulation improver, scar treatment, dry stomach, eye nourishment, abdominal obesity treatment, anti-soil agent, respiratory solvent, and antifungal agent. It also provides prescription drugs, including endocrine system, corticosteroids, fire extinguishing system, circulatory system, psychotropic solvents, tumor therapy, analgesic anti-inflammatory, cutaneous urinary system, antiviral, antibiotics, and respiratory system. In addition, the company offers hair dye, cosmetics, health functional supplements, nasal spray, household goods, muscle taping, disinfectant, toothpaste, anti-hair loss shampoo, and sanitary napkin. The company was founded in 1957 and is headquartered in Seoul, South Korea.

Largest shareholders

  • UAMCO Co. Ltd. (Private Equity)41.40%
  • Taekwang Industrial Co., Ltd.31.05%
  • Brand Refactoring Co. Ltd.3.97%
  • Dong Sung Bio Pharm.Co.,Ltd.2.29%
  • Kyeong-hee Lee0.00771 %0.01%

Share of the company, as of September 25, 2026

Leadership

  • Won-gyun Na — Chairman & CEO, 39
  • Young-ja Oh — Managing Director, 64
  • Cheol-woo Kim — Managing Director, 60
  • Sang-hyeon Park — Managing Director, 58

How much revenue does Dong Sung Bio Pharm.Co.,Ltd. make?

Dong Sung Bio Pharm.Co.,Ltd. reported 87.17 billion KRW in revenue for fiscal year 2025, down 1.4% from 88.45 billion KRW in fiscal year 2024.

What companies are similar to Dong Sung Bio Pharm.Co.,Ltd.?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Ahn-Gook Pharmaceutical Co., Ltd. (001540.KQ), Jeil Pharma Holdings Inc (002620.KS), Handok Inc. (002390.KS), Withus Pharmaceutical Co.,LTD. (330350.KQ).

Has Dong Sung Bio Pharm.Co.,Ltd. made a profit in recent years?

Net income by fiscal year: FY2021, a loss of 4.31 billion KRW; FY2022, a loss of 2.12 billion KRW; FY2023, a loss of 2.07 billion KRW; FY2024, a loss of 7.25 billion KRW; FY2025, a loss of 25.74 billion KRW. It reported a net loss in each of these 5 years.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees298
HeadquartersSeoul, South Korea
ExchangeKSE
TimezoneAsia/Seoul (KST)

Contact & Links

Address
Dongsung Building, Seoul, 01340
Phone
82 2 6911 3600
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Dong Sung Bio Pharm.Co.,Ltd. (002210.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/002210.KS

LinkedInLinkedInXXYouTubeYouTube